Clinical trials: Persistent Thrombocytopenia
Persistent Immune Thrombocytopenia
Management of Children With Persistent ITP, A Novel Approach
The goal of this clinical trial is to learn if mini-pool intravenous immunoglobulin (IVIG) is a safe and effective treatment for children with persistent immune thrombocytopenia (ITP).
- Trial name
- LMICs (NCT07068126)
- Testing
- Mini-Pool IVIG
- Where
- 3 sites in Egypt
- Volunteers
- 20 people
- Sponsor
- Assiut University
Immune Thrombocytopenia
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
This was a randomized, double-blind study of rilzabrutinib in patients with persistent or chronic ITP, with an average platelet count of <30,000/μL (and no single platelet count >35,000/μL) on two counts at least 5 days apart in…
- Trial name
- LUNA 3 (NCT04562766)
- Testing
- Rilzabrutinib
- Where
- 155 sites in United States, Argentina and 24 more
- Volunteers
- 232 people
- Sponsor
- Principia Biopharma, a Sanofi Company
Idiopathic Thrombocytopenic Purpura
The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.
Using eltronmobag as an alternative pathway, which depend on stimulation of thrombocyte synthesis, in chronic and persistent immune thrombocytopenia may be more promising treatment than the classic type, not only by increasing…
- Trial name
- NCT03412188
- Testing
- Eltrombopag, conventional
- Where
- Egypt
- Volunteers
- 36 people
- Sponsor
- Nayera Hazaa Elsherif
Primary Immune Thrombocytopenia (ITP)
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This multicenter randomized, open-label study aim to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or…
- Trial name
- NCT05718856
- Testing
- TPO-RAs, TPO-RAs combining anti-CD 20 monoclonal antibody
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenia, Platelet Disorder
Safety and Efficacy of Eltrombopag at Escalated Doses
Study rationale is based on the data that in previous clinical studies of eltrombopag in ITP there are some patients who have been reported as non responders at the maximal approved dose of 75 mg daily.
- Trial name
- NCT01880047
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Weill Medical College of Cornell University
Immune Thrombocytopenia (ITP)
National Multicenter Retrospective Real-World Study on the Treatment Status of Newly Diagnosed and Persistent Primary Immune Thrombocytopenia (ITP) Patients
This study is a nationwide, multicenter, retrospective, real-world, non-interventional (observational) investigation. It retrospectively collects data on treatment modalities and therapeutic responses in patients with newly…
- Trial name
- NCT07268898
- Volunteers
- 500 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China